Pharma’s Research
Aaron Carroll September 24, 2010
Kevin Drum has a piece up discussing Megan McArdle citing Derick Rowe: Via Megan McArdle, Derek Lowe blogs today about an entire field of pharmaceutical
Kevin Drum has a piece up discussing Megan McArdle citing Derick Rowe: Via Megan McArdle, Derek Lowe blogs today about an entire field of pharmaceutical
By now you know the story. If not, it’s here. I just want the 2010 CBO projections to be in the same format as the
Applying Propensity Score Methods in Medical Research: Pitfalls and Prospects, by Zhehui Luo, Joseph C. Gardiner, and Cathy J. Bradley. The authors review experimental and
Sorry, everyone. I was traveling and needed to focus on what I was doing. I haven’t been able to answer all the great comments and
Uwe Reinhardt got about 90% of the way toward reading my mind in his Economix post this morning. There are a few elements of it
Of all the components of Medicare, Part D–its drug benefit–is perhaps the best run and the most sensible, though still very far from perfect. Yet,
My latest Kaiser Health News column is co-authored by Rex Santerre. It’s about the role of health facilities of different ownership types, including public facilities.
If you haven’t read the introduction, go back and read it now. That introductory post also includes links to all the posts in this series
Work posted here under copyright © of the authors • Details on the Site Policies page
